Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. - Wikidata - wikimedia - TriplyDB

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

http://www.wikidata.org/entity/Q35880493

about

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells Interplay between Fanconi anemia and homologous recombination pathways in genome integrity Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer Current approaches in treatment of triple-negative breast cancer Can nanomedicines kill cancer stem cells?EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors Genetically engineered mouse models in oncology research and cancer medicine Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer Topoisomerase levels determine chemotherapy responsein vitroandin vivo Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in Saccharomyces cerevisiae Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells.A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors In vivo models in breast cancer research: progress, challenges and future directions.Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy Monitoring of tumor response to Cisplatin using optical spectroscopy.The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.Context-dependent bidirectional regulation of the MutS homolog 2 by transforming growth factor β contributes to chemoresistance in breast cancer cells.Secondary mutations of BRCA1/2 and drug resistance ABC transporters: unvalidated therapeutic targets in cancer and the CNS An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.Drug therapy for hereditary cancers Increased levels of choline metabolites are an early marker of docetaxel treatment response in BRCA1-mutated mouse mammary tumors: an assessment by ex vivo proton magnetic resonance spectroscopy Differential remodeling of extracellular matrices by breast cancer initiating cells.Personalized targeted therapy for esophageal squamous cell carcinoma.Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer Whole genomes redefine the mutational landscape of pancreatic cancer.Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?Replication fork stability confers chemoresistance in BRCA-deficient cells Non-germline genetically engineered mouse models for translational cancer research.

P2860

Q24600350-5AB648BF-9E17-4888-B79D-3BCD36C486D1 Q24632628-DAF0183B-1B0A-4E7B-8A13-110A52070ED3 Q24644255-5F43B420-1F1A-4AB4-8C89-FE226FD444B2 Q26748850-CA3C729B-501E-403E-B04A-3F4F74825C7F Q26753126-95623D30-CB06-4E5F-8FF0-E8326BECD837 Q26783551-419A6613-2232-48C4-879C-24CFE961E843 Q26801549-BB489B52-BE30-4A3A-8CA7-3AD8E0C729EA Q27022017-150EDA92-B1F1-473F-8F6A-4CEA8570E0AD Q27318449-AF53D483-2EA9-493F-B907-6A4A70CF4A09 Q28079323-8FCCCD9C-7EB8-4FE4-9C9E-BD9C135ECB7B Q28372484-AE45331D-12C5-4A3D-88CA-9CB8A134A0E0 Q28505250-1A87FCE3-D2B4-4FAC-82BF-C05CBBDDD515 Q28538059-15B665CD-E72D-49EB-9C76-6E991983C502 Q29395563-FF55DE7F-79DD-47EC-B2B6-2E68CC76AB3F Q33463362-78817651-875E-4EE4-94D4-989B474C5583 Q33527780-673B06A2-E387-43FC-9737-64C94E54FC72 Q33575946-AC95A713-7AF4-4CE7-AAE2-2FF1E0A3C2EF Q33588117-3D97BD4C-573B-4B6B-8ED9-73FCE59F43DF Q33788519-3347298B-C573-43D8-89FB-0962C47811D2 Q33827045-93E3E4AB-6377-4A92-89A8-25BCF75FEBE1 Q33912319-ACDC34B5-F259-45FD-B81D-67B069329521 Q34102670-C963ABCC-2E3E-458A-8F0D-04B14147C768 Q34520145-AB375413-AADF-49F2-B9BE-ADEFA78B0FE6 Q34539782-BC044C5D-2C57-4B4A-BD61-B7491E281FE8 Q34619763-C66EFF59-A836-48CE-A0FD-9C52760D6118 Q34688096-BB2DEDEB-A176-4791-9ED7-A93B2EFCA980 Q34983549-0218947E-2007-4BF2-84B3-73E4FC8D104D Q35056738-8B026D29-CE22-4233-894F-DEC9A3CF4616 Q35064705-2C59D325-96E6-4AEA-919C-6C60800B6D73 Q35208929-71A744BB-36F2-4D80-BD98-F47035CC4FBC Q35497704-D33ECF10-7889-404A-9572-A1253F5F0A13 Q35544277-8C97CF2D-FA0C-42EE-8D72-7ECE80C1CC61 Q35819517-6D2E6DC1-300F-4DEB-B98B-C767C026E1C7 Q35845827-57894DA4-9A85-4BE9-BCA7-C9F50F6BC7B4 Q35901185-3189D472-1BDA-4C47-85E3-A49A87700A4C Q35911034-2E4D0D56-F1E0-4B84-9433-8D4F56D213DE Q35917703-FA1612E1-533E-444C-9420-BE444D48473B Q36037500-7E3B8FF4-0AF1-4656-8BF6-15E0E66F75E1 Q36083474-230E62F0-697A-4133-B3AA-B8803C5F841F Q36150711-D93C1BAA-B3BE-4F0C-8466-07EA91CDFE28

P2860

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

http://www.wikidata.org/entity/Q35880493

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Selective induction of chemoth ...... for hereditary breast cancer.

@ast

Selective induction of chemoth ...... for hereditary breast cancer.

@en

type

label

Selective induction of chemoth ...... for hereditary breast cancer.

@ast

Selective induction of chemoth ...... for hereditary breast cancer.

@en

prefLabel

Selective induction of chemoth ...... for hereditary breast cancer.

@ast

Selective induction of chemoth ...... for hereditary breast cancer.

@en

P1433

Q35880493-57073BAF-E568-40D5-9965-6347DACB5552

P1476

Q35880493-8F5C108B-651D-4319-B01A-C1323C9869FF

P2093

Q35880493-1E66D0F7-4897-4723-9C6C-C5A0F2B87666

Q35880493-29BB8847-ED50-4508-A26A-C519CF45FFC9

Q35880493-3ABCEC09-1506-49BE-A0CD-7ABD0F3ABFEF

Q35880493-48AD1A4D-1EEA-44B3-95EE-E992AB3E4DDD

Q35880493-59139D98-CF29-4A8A-B4A5-C450A2415E98

Q35880493-69CF3A67-6E27-4B6F-A374-0BCCB95D0501

Q35880493-6FC39AB2-8871-4E61-9B2E-AFF945562A49

Q35880493-AD4EF5B6-B57B-4D3C-9951-349E927E7EBB

Q35880493-E0FDFD13-F822-4C55-B207-FA93DE30B6BB

Q35880493-EF71D371-8D99-44CA-91A1-50F1CFA78A22

P2860

Q35880493-01A41C2D-0CD3-4808-AECF-8D3E658933EA

Q35880493-0545E38E-53F1-4E28-B51F-2A2A08B66C87

Q35880493-09B1558D-532D-49A2-9C6C-7B4FD0D92948

Q35880493-0D8DA7AA-414F-4F10-A338-4A2B72ACEE52

Q35880493-10033A8C-BBA0-4A76-8E5D-247E579FED9E

Q35880493-139EC46B-80A8-4366-869D-1C1647D017BD

Q35880493-14A4B4FB-097F-45BC-8CA9-9E1214A3111F

Q35880493-25AB41D5-E1C9-4CB4-B2C0-AA3E6C3146AC

Q35880493-2674A914-76AA-4B58-81A8-68894EF355F5

Q35880493-2969447C-492E-4D35-A6B6-56904DB79F1D

P304

Q35880493-21161EE7-C8ED-4462-B453-D4FD7460B928

P31

Q35880493-DF689A5E-6663-4266-9C8B-7B6A179CFA39

P356

Q35880493-4455067F-F14C-47C5-845A-85EB49AA1B97

P407

Q35880493-A115E34C-6E05-41DB-84F0-07604386866A

P433

Q35880493-B540F8C8-C74E-45D2-B9C3-871E31DA4BF8

P478

Q35880493-C3F023DA-4296-46CD-B934-DDEC3B01491E

P50

Q35880493-92F6FF3B-F2F3-49D0-8199-391AED52C3D5

Q35880493-A85B544A-F289-419E-A80E-1F145E949AC3

P577

Q35880493-9068D72C-7D5D-45BD-88E7-85B3C71D6738

P5875

Q35880493-171A3A95-7A9F-4DFC-99D4-C8A5CA1D9370

P698

Q35880493-81B824D9-E592-4C05-882E-58A7A36615A8

P921

Q35880493-59BCB526-797C-43CB-8DA3-27A4C25323C2

P932

Q35880493-C0ADE631-4A52-46BC-B702-BA4F90EE5FD1

P356

PNAS.0702955104

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Selective induction of chemoth ...... for hereditary breast cancer.

@en

P2093

Anders O H Nygren

http://www.w3.org/2001/XMLSchema#string

Fijs W B van Leeuwen

http://www.w3.org/2001/XMLSchema#string

Ingrid van der Heijden

http://www.w3.org/2001/XMLSchema#string

Jan P Schouten

http://www.w3.org/2001/XMLSchema#string

Jos Jonkers

http://www.w3.org/2001/XMLSchema#string

Karin E de Visser

http://www.w3.org/2001/XMLSchema#string

Kenneth G Gilhuijs

http://www.w3.org/2001/XMLSchema#string

Koen van de Wetering

http://www.w3.org/2001/XMLSchema#string

Olaf van Tellingen

http://www.w3.org/2001/XMLSchema#string

Piet Borst

http://www.w3.org/2001/XMLSchema#string

P2860

Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification

Rapid and quantitative detection of homologous and non-homologous recombination events using three oligonucleotide MLPA.

Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer--a prospective clinical study

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Drug penetration in solid tumours

Mechanisms of cancer drug resistance

Generation of a functional mammary gland from a single stem cell

Purification and unique properties of mammary epithelial stem cells

P304

12117-12122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0702955104

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

Sven Rottenberg

P577

2007-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6212359

http://www.w3.org/2001/XMLSchema#string

P698

17626183

http://www.w3.org/2001/XMLSchema#string

P921

P932

1914039

http://www.w3.org/2001/XMLSchema#string